This is your fourth of seven free items this month.

To register, get added benefits and unlimited access to articles, Become a Member. Already a Member? Sign in.

J. WALTER THOMPSON DROPPED FROM CELEBREX WORK

Kaplan Thaler and Arnold Compete for $81 Million Pfizer Account

By Published on . 0

NEW YORK (AdAge.com) -- Pfizer is dropping WPP Group's J. Walter Thompson from the advertising account for its anti-arthritis drug Celebrex,
Also Today:
THREE AGENCIES GET $126 MILLION IN PFIZER AD WORK
Includes Zyrtec, Zoloft and Bextra Accounts

according to the pharmaceutical company.

Two contenders
Publicis Groupe's Kaplan Thaler Group, New York, and Havas' Arnold Worldwide, Boston, will now compete for the $81 million account, the company said. Arnold was a finalist in the review for Zoloft and the cholesterol drug Bextra, and was asked by the company to compete against Kaplan Thaler for Celebrex.

Celebrex is the market leader in anti-arthritis medication with 2002 sales of $3.05 billion, topping competitor Vioxx, from Merck, which had $2.5 billion in sales last year.

Read These Next